BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moser T, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J. Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol 2020;7:2199-212. [PMID: 33002321 DOI: 10.1002/acn3.51206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Moser T, Hoepner L, Schwenker K, Seiberl M, Feige J, Akgün K, Haschke-Becher E, Ziemssen T, Sellner J. Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis. Cells 2021;10:3116. [PMID: 34831335 DOI: 10.3390/cells10113116] [Reference Citation Analysis]
2 Moser T, O'Sullivan C, Puttinger C, Feige J, Pilz G, Haschke-Becher E, Cadamuro J, Oberkofler H, Hitzl W, Harrer A, Kraus J, Trinka E, Wipfler P. Pre-Existing Humoral Immunological Memory Is Retained in Patients with Multiple Sclerosis Receiving Cladribine Therapy. Biomedicines 2021;9:1584. [PMID: 34829815 DOI: 10.3390/biomedicines9111584] [Reference Citation Analysis]
3 Winkelmann A, Loebermann M, Barnett M, Hartung HP, Zettl UK. Vaccination and immunotherapies in neuroimmunological diseases. Nat Rev Neurol 2022. [PMID: 35388213 DOI: 10.1038/s41582-022-00646-5] [Reference Citation Analysis]
4 Tobias M, Ferdinand O, Ciara O, Wolfgang H, Georg P, Andrea H, Eugen T, Peter W. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications – a pilot study. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.103560] [Reference Citation Analysis]
5 Allen-philbey K, De Trane S, Mao Z, Álvarez-gonzález C, Mathews J, Macdougall A, Stennett A, Zhou X, Yildiz O, Adams A, Bianchi L, Blain C, Chapman C, Chung K, Constantinescu CS, Dalton C, Farrell RA, Fisniku L, Ford H, Gran B, Hobart J, Khaleeli Z, Mattoscio M, Pavitt S, Pearson O, Peruzzotti-jametti L, Scalfari A, Sharrack B, Silber E, Tallantyre EC, Webb S, Turner BP, Marta M, Gnanapavan S, Juliusson G, Giovannoni G, Baker D, Schmierer K. Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. Ther Adv Neurol Disord 2021;14:175628642110576. [DOI: 10.1177/17562864211057661] [Reference Citation Analysis]
6 Dobreanu M, Manu DR, Mănescu IB, Gabor MR, Huţanu A, Bărcuţean L, Bălaşa R. Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An In Vitro Study. Front Immunol 2021;12:743010. [PMID: 34970256 DOI: 10.3389/fimmu.2021.743010] [Reference Citation Analysis]
7 Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T. HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES. Mult Scler Relat Disord 2021;54:103150. [PMID: 34298478 DOI: 10.1016/j.msard.2021.103150] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel) 2021;9:99. [PMID: 33525459 DOI: 10.3390/vaccines9020099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
9 Spiezia AL, Cerbone V, Molinari EA, Capasso N, Lanzillo R, Carotenuto A, Petracca M, Novarella F, Covelli B, Scalia G, Brescia Morra V, Moccia M. Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis. Mult Scler Relat Disord 2021;57:103431. [PMID: 34871857 DOI: 10.1016/j.msard.2021.103431] [Reference Citation Analysis]
10 Fissolo N, Calvo-Barreiro L, Eixarch H, Boschert U, Espejo C, Montalban X, Comabella M. Immunomodulatory Effects Associated with Cladribine Treatment. Cells 2021;10:3488. [PMID: 34943995 DOI: 10.3390/cells10123488] [Reference Citation Analysis]
11 Zarobkiewicz MK, Morawska I, Michalski A, Roliński J, Bojarska-Junak A. NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome. Int J Mol Sci 2021;22:9520. [PMID: 34502425 DOI: 10.3390/ijms22179520] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Anwar MM. Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. J Immunoassay Immunochem 2020;41:960-75. [PMID: 33393415 DOI: 10.1080/15321819.2020.1865400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Maniscalco GT, Manzo V, Ferrara AL, Perrella A, Di Battista M, Salvatore S, Graziano D, Viola A, Amato G, Moreggia O, Di Giulio Cesare D, Barbato S, Servillo G, Longo K, Di Giovanni M, Scarpati B, Muggianu SM, Longo G, Russo G, Andreone V, De Rosa V. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. Multiple Sclerosis and Related Disorders 2022;58:103455. [DOI: 10.1016/j.msard.2021.103455] [Reference Citation Analysis]
14 Giovannoni G, Mathews J. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. Neurol Ther 2022;11:571-95. [PMID: 35318617 DOI: 10.1007/s40120-022-00339-7] [Reference Citation Analysis]
15 Seferoğlu M, Ethemoğlu Ö, Turan ÖF, Siva A. MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine. Neurol Sci 2021;42:3533-5. [PMID: 34165650 DOI: 10.1007/s10072-021-05409-6] [Reference Citation Analysis]
16 Koldej RM, Prabahran A, Tan CW, Ng AP, Davis MJ, Ritchie DS. Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers. Sci Rep 2021;11:19056. [PMID: 34561502 DOI: 10.1038/s41598-021-98536-1] [Reference Citation Analysis]
17 Moser T, Ziemssen T, Sellner J. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety. Wien Med Wochenschr 2022. [PMID: 35451662 DOI: 10.1007/s10354-022-00931-4] [Reference Citation Analysis]
18 Veroni C, Aloisi F. The CD8 T Cell-Epstein-Barr Virus-B Cell Trialogue: A Central Issue in Multiple Sclerosis Pathogenesis. Front Immunol 2021;12:665718. [PMID: 34305896 DOI: 10.3389/fimmu.2021.665718] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Radlberger RF, Sakic I, Moser T, Pilz G, Harrer A, Wipfler P. Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. Mult Scler Relat Disord 2021;48:102727. [PMID: 33418308 DOI: 10.1016/j.msard.2020.102727] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]